To improve the affinity of antibodies, recent studies have genetically modified the binding domains of human PD‐1 and SIRPα, with engineered variants dramatically increasing affinity to their ligands and improving their penetration of targeting tumours (Maute et al., 2015; Weiskopf et al., 2013). Here, SIRPA is linked to neoplasm.